Gritstone bio (GRTS) Scheduled to Post Quarterly Earnings on Thursday

Gritstone bio (NASDAQ:GRTS) will be announcing its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Gritstone bio (NASDAQ:GRTS) last announced its quarterly earnings results on Tuesday, March 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.10. Gritstone bio had a negative return on equity of 147.22% and a negative net margin of 847.24%. The business had revenue of $10.38 million for the quarter, compared to analyst estimates of $4.80 million. On average, analysts expect Gritstone bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gritstone bio Trading Up 5.0 %

NASDAQ GRTS opened at $1.01 on Wednesday. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.77. Gritstone bio has a 52 week low of $0.67 and a 52 week high of $3.33. The business has a 50 day moving average price of $1.66 and a 200-day moving average price of $1.88. The company has a market cap of $108.20 million, a price-to-earnings ratio of -0.84 and a beta of 0.64.

Wall Street Analyst Weigh In

A number of analysts have commented on GRTS shares. JMP Securities boosted their price target on shares of Gritstone bio from $4.00 to $5.00 and gave the company a “market outperform” rating in a research note on Tuesday, April 2nd. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Gritstone bio in a research report on Wednesday, March 6th.

About Gritstone bio

Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.